These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23004926)

  • 1. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
    Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
    J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis].
    Hund M; Sinkgraven R; Rzany B
    J Dtsch Dermatol Ges; 2004 May; 2(5):343-9. PubMed ID: 16281522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin A for axillary hyperhidrosis (excessive sweating).
    Heckmann M; Ceballos-Baumann AO; Plewig G;
    N Engl J Med; 2001 Feb; 344(7):488-93. PubMed ID: 11172190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M; Lowe NJ; Kumar CR; Hamm H;
    Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
    Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
    J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial.
    Ibrahim O; Kakar R; Bolotin D; Nodzenski M; Disphanurat W; Pace N; Becker L; West DP; Poon E; Veledar E; Alam M
    J Am Acad Dermatol; 2013 Jul; 69(1):88-95. PubMed ID: 23591103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis.
    Paul A; Kranz G; Schindl A; Kranz GS; Auff E; Sycha T
    Lasers Surg Med; 2010 Mar; 42(3):211-4. PubMed ID: 20333738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
    Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
    Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
    Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
    Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis: a pilot exploratory trial.
    Innocenzi D; Lupi F; Bruni F; Frasca M; Panetta C; Milani M
    Curr Med Res Opin; 2005 Dec; 21(12):1949-53. PubMed ID: 16368045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
    Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival.
    Campanati A; Sandroni L; Gesuita R; Giuliano A; Giuliodori K; Marconi B; Ganzetti G; Offidani A
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):917-21. PubMed ID: 21054569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis.
    Talarico-Filho S; Mendonça DO Nascimento M; Sperandeo DE Macedo F; DE Sanctis Pecora C
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S44-50. PubMed ID: 17241414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
    Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
    Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
    Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
    J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.
    Heckmann M; Plewig G;
    Arch Dermatol; 2005 Oct; 141(10):1255-9. PubMed ID: 16230563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up.
    Caplin D; Austin J
    J Drugs Dermatol; 2014 Apr; 13(4):449-56. PubMed ID: 24719065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.